Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD

Chest

Volumn 143, Issue 4, 2013, Pages 1009-1017

  Crisafulli, Ernesto ^a   Menéndez, Rosario ^b   Huerta, Arturo ^c   Martinez, Raquel ^b   Montull, Beatriz ^b   Clini, Enrico ^a   Torres, Antoni ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; C REACTIVE PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LONG ACTING DRUG; PROCALCITONIN; SHORT ACTING DRUG; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOME CARE; HOSPITAL READMISSION; HUMAN; INFLAMMATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SPAIN; SPIROMETRY; VIRUS PNEUMONIA;

EID: 84875978870     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1684     Document Type: Article

References (42)

1. Menéndez R, Martinez R, Reyes S, et al. Stability in community- acquired pneumonia: one step forward with markers? Thorax. 2009; 64 (11): 987-992.
2. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174 (1): 84-93.
3. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009; 302 (10): 1059-1066.
4. Remmelts HH, Meijvis SC, Heijligenberg R, et al. Biomarkers define the clinical response to dexamethasone in communityacquired pneumonia. J Infect. 2012; 65 (1): 25-31.
5. Zobel K, Martus P, Pletz MW, et al; CAPNETZ study group. Interleukin 6, lipopolysaccharide-binding protein and interleukin 10 in the prediction of risk and etiologic patterns in patients with community-acquired pneumonia: results from the German competence network CAPNETZ. BMC Pulm Med. 2012; 12-6.
6. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008; 63 (5): 447-452.
7. Menéndez R, Martínez R, Reyes S, et al. Biomarkers improve mortality prediction by prognostic scales in communityacquired pneumonia. Thorax. 2009; 64 (7): 587-591.
8. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J. 2011; 37 (6): 1439-1446.
9. Reade MC, Yende S, D'Angelo G, et al Genetic and Inflammatory Markers of Sepsis Investigators. Differences in immune response may explain lower survival among older men with pneumonia. Crit Care Med. 2009; 37 (5): 1655-1662.
10. Krüger S, Ewig S, Marre R, et al CAPNETZ Study Group. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J. 2008; 31 (2): 349-355.
11. Horie M, Ugajin M, Suzuki M, et al. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia . Am J Med Sci. 2012; 343 (1): 30-35.
12. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report, NIH Publication 2701. http://www.goldcopd.com/. Updated November 2006. Accessed April 2012.
13. Garcia-Rio F, Miravitlles M, Soriano JB, et al EPI-SCAN Steering Committee. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res. 2010; 11-63.
14. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574-580.
15. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008; 5 (4): 478-485.
16. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128 (4): 2099-2107.
17. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. 2012; 106 (8): 1124-1133.
18. Liapikou A, Polverino E, Ewig S, et al. Severity and outcomes of hospitalised community-acquired pneumonia in COPD patients. Eur Respir J. 2012; 39 (4): 855-861.
19. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med. 2007; 101 (10): 2139-2144.
20. Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by communityacquired pneumonia. Eur Respir J. 2006; 27 (6): 1210-1216.
21. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with communityacquired pneumonia. Eur Respir J. 2006; 28 (2): 346-351.
22. Molinos L, Clemente MG, Miranda B, et al ASTURPAR Group. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009; 58 (6): 417-424.
23. Menéndez R, Torres A, Zalacaín R, et al Neumofail Group. Risk factors of treatment failure in community acquired pneu monia: implications for disease outcome. Thorax. 2004; 59 (11): 960-965.
24. Snijders D, van der Eerden M, de Graaff C, Boersma W. The influence of COPD on mortality and severity scoring in community-acquired pneumonia. Respiration. 2010; 79 (1): 46-53.
25. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC; Official Statement of the European Respiratory Society. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society Eur Respir J Suppl. 1993; 16 : 5-40.
26. de Roux A, Cavalcanti M, Marcos MA, et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest. 2006; 129 (5): 1219-1225.
27. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia . N Engl J Med. 1997; 336 (4): 243-250.
28. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58 (5): 377-382.
29. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med. 2002; 162 (16): 1849-1858.
30. Endeman H, Meijvis SC, Rijkers GT, et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J. 2011; 37 (6): 1431-1438.
31. Kolling UK, Hansen F, Braun J, Rink L, Katus HA, Dalhoff K. Leucocyte response and anti-inflammatory cytok ines in community acquired pneumonia. Thorax. 2001; 56(2): 121-125.
32. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest. 2001; 119 (suppl 2): 419S-425S.
33. Gutierrez P, Closa D, Piñer R, Bulbena O, Menéndez R, Torres A. Macrophage activation in exacerbated COPD with and without community-acquired pneumonia. Eur Respir J. 2010; 36 (2): 285-291.
34. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J. 2010; 35 (5): 1039-1047.
35. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3 (1): 23-35.
36. Donnelly LE, Barnes PJ. Defective phagocytosis in airways disease. Chest. 2012; 141 (4): 1055-1062.
37. Berenson CS, Garlipp MA, Grove LJ, Maloney J, Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis. 2006; 194 (10): 1375-1384.
38. Calverley PMA, Stockley RA, Seemungal TA, et al Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011; 139 (3): 505-512.
39. Almirall J, Bolíbar I, Serra-Prat M, et al Community-Acquired Pneumonia in Catalan Countries. Inhaled drugs as risk factors for community-acquired pneumonia. Eur Respir J. 2010; 36 (5): 1080-1087.
40. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170 (7): 760-765.
41. Antoniu SA. Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. Biomarkers. 2010; 15 (2): 97-103.
42. Montón C, Ewig S, Torres A, et al. Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J. 1999; 14 (1): 218-220.